Francis Knuettel II - Feb 15, 2024 Form 3 Insider Report for Chromocell Therapeutics Corp (CHRO)

Role
Interim CEO, CFO, Treas & Sec
Signature
/s/ Francis Knuettel II
Stock symbol
CHRO
Transactions as of
Feb 15, 2024
Transactions value $
$0
Form type
3
Date filed
2/15/2024, 08:10 PM
Previous filing
Sep 8, 2023
Next filing
Feb 23, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CHRO Stock Options Feb 15, 2024 Common Stock 22.2K $22.68 Camden Capital LLC F1, F2
holding CHRO Stock Options Feb 15, 2024 Common Stock 2.78K $22.68 Camden Capital LLC F1, F3
holding CHRO Stock Options Feb 15, 2024 Common Stock 27.8K $22.68 Camden Capital LLC F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.
F2 On January 10, 2023, Camden Capital LLC was granted stock options to purchase 22,223 shares of common stock at an exercise price of $22.68 per share. 2,223 shares of such options became exercisable on October 1, 2022, 2,223 shares of such options became exercisable on January 1, 2023, 2,223 shares of such options became exercisable on April 1, 2023, 2,223 shares of such options became exercisable on July 1, 2023, 2,223 shares were vested on October 1, 2023, 2,223 shares were vested on January 1, 2024, 2,223 shares will vest on April 1, 2024 and the remaining 6,662 shares of such options shall become exercisable in equal installments on a quarterly basis, subject to the Reporting Person's continued service to Issuer. The final installment shall become exercisable on January 1, 2025, subject to the Reporting Person's continued service to Issuer.
F3 On January 10, 2023, Camden Capital LLC was granted stock options to purchase 2,778 shares of common stock at an exercise price of $22.68 per share, which shall become exercisable upon the closing of Issuer's initial public offering.
F4 On June 23, 2023, Camden Capital LLC was granted stock options to purchase 27,778 shares of common stock at an exercise price of $22.68 per share, which shall become exercisable within thirty (30) days of the closing of Issuer's initial public offering.

Remarks:

Exhibit 24 - Power of Attorney